INSIDERFilingvia Quantisnow
Kintara Therapeutics Inc. logo

Kintara Therapeutics (KTRA) executive Praill acquired 938 shares

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Anthony Scott Praill (executive at Kintara Therapeutics Inc., KTRA) reported that they acquired 938 shares, and acquired 8 shares on Apr 29, 2021. After these transactions the filing shows 8,486 shares held directly.

Reporting person
Praill Anthony Scott
Common stock and other non-derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Apr 29, 2021Other acquisition or disposition (J)Common Stock1+8--7,548 direct
Apr 29, 2021Conversion of a derivative (C)Common Stock2, 3+938--8,486 direct

Options and other derivatives

Options and other derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Apr 29, 2021Conversion of a derivative (C)Series B Convertible Preferred StockOn 938 Common Stock2, 3-3,750--0 direct

Holdings before and after

  • Common Stock: 7,540 to 8,486 direct
  • Series B Convertible Preferred Stock: 3,750 to 0 direct

Footnotes from the filing

  1. 1. The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock.
  2. 2. Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.
  3. 3. Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00.

Transaction codes in this filing

Conversion of a derivative:
Code C marks the conversion of a derivative, such as preferred stock or units, into another security.
Other acquisition or disposition:
Code J marks a transaction that fits no other code. The footnotes describe what happened.

FAQ

What did Praill report in this KTRA Form 4?

Anthony Scott Praill (executive at Kintara Therapeutics Inc., KTRA) reported that they acquired 938 shares, and acquired 8 shares on Apr 29, 2021. After these transactions the filing shows 8,486 shares held directly.

How many KTRA shares does Praill hold after this filing?

The filing shows 8,486 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.

What does transaction code C mean on an SEC Form 4?

Code C marks the conversion of a derivative, such as preferred stock or units, into another security.

Historical context for KTRA

Earlier insider filings at KTRA

Quantisnow market dataNASDAQ
Kintara Therapeutics Inc. logo
KTRA
Kintara Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Get push alerts for KTRA

Follow KTRA and get a push notification the moment its next story breaks.

Full KTRA profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KTRA (Kintara Therapeutics Inc.) and more on Quantisnow.